Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
Dexamethasone showed no clear difference in any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
Dexamethasone showed no clear difference in respiratory distress syndrome compared with betamethasone – fetal/neonatal outcomes (high certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
Dexamethasone showed no clear difference in intraventricular haemorrhage compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
Dexamethasone showed no clear difference in chronic lung disease compared with betamethasone – fetal/neonatal outcomes (moderate certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
Dexamethasone showed no clear difference in necrotising enterocolitis compared with betamethasone – fetal/neonatal outcomes (low certainty).
1 finding from 1 review
Pain / clinical response (not analysable) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
1 finding from 1 review
Clearing or excellent improvement · people with discoid lupus erythematosus
1 finding from 1 review
At least 50% reduction in erythema · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life measure · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
Incidence of RDS frequency in newborns · women at risk of preterm birth
Ambroxol showed no clear difference in incidence of RDS frequency in newborns compared with corticosteroid (betamethasone) (moderate certainty).
1 finding from 1 review
Perinatal mortality frequency of deaths of newborns · women at risk of preterm birth
Ambroxol showed no clear difference in perinatal mortality frequency of deaths of newborns compared with corticosteroid (betamethasone) (moderate certainty).
1 finding from 1 review
Adverse effects in pregnant women frequency in pregnant women · women at risk of preterm birth
It is very uncertain whether ambroxol changes adverse effects in pregnant women frequency in pregnant women compared with corticosteroid (betamethasone) (very low certainty).
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus
1 finding from 1 review
Complications (adverse effects) · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Intra-articular injection of sodium hyaluronate showed no clear difference in complications (adverse effects) compared with intra-articular injection of corticosteroids (betamethasone); GRADE not reported.
1 finding from 1 review